Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Cognition, Age, and RaPamycin Effectiveness - DownregulatIon of thE mTor Pathway (CARPE DIEM)
Authors not listed
The University of Texas Health Science Center at San Antonio · 2020
Abstract
Evaluation of central nervous system penetration of orally administered Rapamune (RAPA) in older adults with Mild Cognitive Impairment (MCI) or early Alzheimer's disease (AD) and investigate associated safety, tolerability, target engagement, cognition, and functional status as initial proof-of-concept study
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-13 MST
Cite this
APA
Anonymous. (2020). Cognition, Age, and RaPamycin Effectiveness - DownregulatIon of thE mTor Pathway (CARPE DIEM). <em>The University of Texas Health Science Center at San Antonio</em>. https://clinicaltrials.gov/study/NCT04200911
Vancouver
Anonymous. Cognition, Age, and RaPamycin Effectiveness - DownregulatIon of thE mTor Pathway (CARPE DIEM). The University of Texas Health Science Center at San Antonio. 2020.
BibTeX
@misc{anon2020Cognit,
title = {Cognition, Age, and RaPamycin Effectiveness - DownregulatIon of thE mTor Pathway (CARPE DIEM)},
author = {Anonymous},
journal = {The University of Texas Health Science Center at San Antonio},
year = {2020},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Neuroscience & Biobehavioral Reviews 2023
Open access · OA
New perspectives on the basal forebrain cholinergic system in Alzheimer’s disease
Novartis Pharmaceuticals 2021
Open access · US-GOV
Exploratory PLatform Trial on Anti-Inflammatory Agents in Alzheimer's Disease (EXPLAIN-AD): A Randomized, Placebo-controlled, Multicenter Platform Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Various Anti-inflammatory Agents in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
Eli Lilly and Company 2014
Open access · US-GOV
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
The University of Texas Health Science Center at San Antonio 2021
Open access · US-GOV
Pilot Study to Investigate the Safety and Feasibility of AntiRetroviral Therapy for Alzheimer's Disease (ART-AD)
Biomed Industries, Inc. 2018
Open access · US-GOV
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of NA-831 in Alzheimer Patients With Mild Cognitive Impairment
Novartis 2003
Open access · US-GOV